BioSpace News Archive

Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has completed enrollment for both ongoing global Phase 3 VIOLET clinical trials for VT-1161 ahead of schedule, advancing timelines for the company’s pivotal studies.

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time.

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, reported financial results and provided a business update for the three months ended September 30, 2019.

Celldex Therapeutics, Inc. reported business and financial highlights for the third quarter ended September 30, 2019.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for the third quarter ended September 30, 2019

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that the FDA has approved a request for Investigational New Drug (“IND”) status for its drug candidate WP1066 to be used in a Phase 1 clinical trial for the treatment of children with recurrent or refractory malignant brain tumors.

Eagle Genomics is excited to announce its selection as a RisingFoodStar in the European Institute of Innovation and Technology Food’s (EIT Food) RisingFoodStars programme.

Generates repeatable, high-quality semiconductor analysis to accelerate device development and maximize yields

Avanir Pharmaceuticals, Inc. announced that it will continue the clinical development program of AVP-786 for the treatment of agitation in patients with Alzheimer’s dementia.

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received Health Canada approval of CABOMETYX® (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.